Posted by Michael Wonder on 10 Jun 2024
FDA grants fast track designation to GCBP and Novel Pharma's GC1130A
10 June 2024 - GC Biopharma and Novel Pharma have announced that the US FDA has granted fast track designation for their jointly developed MPSIIIA (Sanfilippo syndrome type A) treatment, GC1130A.
This designation follows the FDA's clearance of the investigational new drug application for GC1130A last month.
